Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 06:16 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Penny Stock Picks » Strong Buy: CYTR =MC $10 M-- NDA/MAA filing in Q2 +many Phase 3 and P2 ongoing=LIFETIME OPP



Reply
 
Thread Tools Search this Thread
Old 01-02-2020, 08:20 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Default CYTR =MC $10 M-- NDA/MAA filing in Q2 +many Phase 3 and P2 ongoing=LIFETIME OPP

CYTR= Market-Cap $9.8 M--Cash $18.5 M or untill 2023+ --HUGE Pipeline with multiple Phase 3 & Phase 2 programs targeting Rare Disease and Cancer(links to pipeline charts below) . First NDA & MAA submission expected in Q2 for a Rare Disease (Niemann-Pick Disease) with potential approval in Q4 in USA and Europe which will trigger $10 million milestone payment + royalties to CYTR .Multiple clinical trial readouts expected during first half of this year (more infos below).

This MASSIVE underpriced low float stock could easily rise more than tenfold in the coming months on positive clinical results and approvals . Again Market cap is less than $10 million trading 80% below Cash balance which makes this stock more than a PURE GIFT .STRONG BUY SUPER AGGRESSIVE ,, from current sp its almost a slam dunk .GL


CytRx (CYTR)

Market-Cap: $9,8 M
Cash: $18,5 M ( Cash untill 2023+ )
Price: $0,29

Shares Out: 33,6 M

Burn-rate: only $1.2 M per Quarter
NO Debt



Presentation December 2019
http://www.cytrx.com/wp-content/uplo...9-Non-Conf.pdf


CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin ....December 19, 2019
http://www.cytrx.com/wp-content/uplo...ec19_FINAL.pdf


CytRx Corporation - Biopharmaceutical Company Discusses Near Term Value from Out-License Deals and Growth Drivers
https://stocknewsnow.com/commentary/...on-(OTCQB-CYTR)


Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
https://finance.yahoo.com/news/orpha...060058985.html


Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
https://finance.yahoo.com/news/orpha...060000973.html











Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-02-2020, 12:32 PM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Running higher stock could hit one $1+ very soon ..stock is just a pure gift at current $12 million valuation
https://www.bloomberg.com/quote/CYTR:US
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-03-2020, 08:17 AM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

more good news out today from CYTR´s partner Orphazyme

Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
https://www.globenewswire.com/news-r...se-Type-C.html
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-06-2020, 08:20 AM   Nav to Top  #4
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Market Cap $16 M --Cash $18.5 M or Cash untill 2023+ --NO DEBT --BIG Orphan Drug close to Approval (2H 2020) -three Phase 3 Programs in different Indications ongoing and many in Phase 2 trials -Upcoming MAJOR Milestones + Links to Presentation and Pipeline charts below= The CHEAPEST & BIGGEST Opportunity in the entire Sector ,it has everything to be the minimum next 10+ bagger stock .GL

CytRx (CYTR)

Market-Cap: $16 M
Cash: $18,5 M ( Cash untill 2023+ )
Price: $0,49

Shares Out: 33,6 M

Burn-rate: only $1.2 M per Quarter
NO DEBT

Upcoming Catalysts of the Rare Disease Pipeline partnered with Orphazyme (CYTR will get up to $120 M in potential Milestones + Royalties)

Arimoclomol tested in 4 different indication :

1) Niemann-Pick disease Type C (NPC)--Early access program in January -- NDA/MAA filing in Q2 2020 ---There are no approved treatments for NPC in the USA and only one approved product in Europe. Arimoclomol has been granted Orphan Drug Designation (EU and USA), Rare Pediatric Disease Designation (USA), and Fast Track designation (USA) for the treatment of NPC.

2) Sporadic Inclusion Body Myositis (sIBM) Phase 2/3 interim results in Q1 2020 -- very large market potential --There are no approved treatments for sIBM. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of sIBM.

3) Amyotrophic Lateral Sclerosis (ALS) interim results Q1/Q2 2020 --very large market potential --Currently, there are only limited treatment options available. Arimoclomol has been granted Orphan Drug Designation (EU and USA) for the treatment of ALS.

4) Gaucher disease typ III--Phase 2 results in Q1 ---Effective treatments are available for the systemic manifestations of the disease – however, no therapies are available for the neurological symptoms.



CYTR - Arimoclomol --Rare Disease Pipeline (WW rights acquired by Orphazyme)


CYTR-- Aldoxurubicin-- Cancer Pipeline (partnered with ImmunityBio)
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-06-2020, 08:43 AM   Nav to Top  #5
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Great News out today by drug partner Orphazyme....

Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
https://www.globenewswire.com/news-r...se-Type-C.html

The EAP provides a pathway for patients with serious, life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs before they are approved.

Kim Stratton, Chief Executive Officer, commented, “Orphazyme is deeply committed to providing access to new therapies for people living with rare diseases such as NPC. There are currently no approved products to treat NPC in the US and we are pleased to make arimoclomol, a potential first-in-class innovative oral therapy, available pre-commercially to US patients through this program. We plan to file for approval of arimoclomol in the US in H1 2020”.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-06-2020, 10:37 AM   Nav to Top  #6
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 283
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

EXPLODINGGG again ..still a pure gift under $1

Biohero is offline   Rate this post Yes | No Reply With Quote
Old 04-18-2020, 11:46 PM   Nav to Top  #7
Forepainely
Junior Trader
 
Forepainely's Avatar
 
Join Date: Apr 2020
Location: Boynton
Posts: 1
Favorites: Elite,Mater and
Rep Power: 2
Reputation: 10
Forepainely is on a distinguished road
Default

I have seen that marketing is the essential thing which providing the detail about the many services which can provide good service or good trading options.There are many platform where students looks for the software which can help with click now option and they can easily get some tips of writing work with many other money earning options as well.
Forepainely is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 Ongoing =TOP PICK Biohero US Stock Picks 25 01-18-2018 09:22 AM
Strong Buy: STDY (MC $ 35M) NDA filing in 2H for MEGA Orphan Drug = Lifetime Opportunity Biohero US Stock Picks 4 04-07-2016 03:29 AM
RFMK Opportunity of a lifetime sleepyrizz Trading Questions 0 01-12-2012 09:07 PM
Strong Buy: Technical Breakout Alert Issued for CytRx (NASDAQ:CYTR) StocksHaven US Stock Picks 0 11-23-2009 08:48 AM
Buy: Biovest Inches Closer to Cancer Vaccine NDA Filing (OTC:BVTI) StocksHaven US Penny Stock Picks 10 09-23-2009 10:25 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On